Long-term use of isradipine does not slow Parkinson's progression

Parkinson's disease
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

Long-term treatment with immediate-release isradipine does not seem to slow the clinical progression of early-stage Parkinson's disease. Findings from a multicenter, randomized, parallel-group, double-blind, placebo-controlled trial are published in Annals of Internal Medicine.

Despite multiple prior studies, there are no proven strategies for slowing the progression of Parkinson's disease. Isradipine, a dihydropyridine calcium-channel blocker approved for the treatment of hypertension, has been shown to be neuroprotective in animal models Parkinson's disease. Several have demonstrated a for Parkinson's disease in persons receiving dihydropyridines compared with other antihypertensive agents, leading researchers to hypothesize that isradipine may have the potential to slow the progression of the disease when used in its early stages.

Researchers from the Parkinson Study Group STEADY-PD III Investigators team randomly assigned 336 patients with early-stage Parkinson's disease at 57 Parkinson Study Group sites in North America to either 5 mg of immediate-release isradipine twice daily or placebo for 36 months. None of the participants were taking dopaminergic medications at enrollment. The researchers found no in the change in Unified Parkinson's Disease Rating Scale (UPDRS) scores over 36 months in patients receiving isradipine twice daily versus those receiving placebo. None of the secondary outcome measures demonstrated benefit of isradipine.

According to the researchers, these results do not support the hypothesis that isradipine at this dose slows the progression of early-stage Parkinson's disease.


Explore further

Blood pressure drug shows no benefit in Parkinson's disease

More information: Study: http://annals.org/aim/article/doi/10.7326/M19-2534
Editorial: http://annals.org/aim/article/doi/10.7326/M20-1023
Free Summary for Patients: http://annals.org/aim/article/doi/10.7326/P20-0004
Journal information: Annals of Internal Medicine

Citation: Long-term use of isradipine does not slow Parkinson's progression (2020, March 31) retrieved 1 June 2020 from https://medicalxpress.com/news/2020-03-long-term-isradipine-parkinson.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments